Subscribe

Ship Healthcare Holdings, Inc. (3360.T)

JPY2,298.00 +11.00 (+0.48%)
JP JPX Healthcare Medical - Instruments & Supplies
Address 3-20-8 Kasuga 565-0853
Suita, JP
CEO Futoshi Ohashi
Website shiphd.co.jp
IPO 2005-02-22
ISIN JP3274150006

Explore sections of this company profile

Description

Ship Healthcare Holdings, Inc. is an international enterprise engaged across the medical, healthcare, welfare, and nursing care domains. The company's diverse activities span four primary segments: Total Pack Produce, Medical Supply, Life Care, and Dispensing Pharmacy. The Total Pack Produce segment delivers comprehensive solutions, encompassing large-volume sales of medical devices and equipment, expert consulting for various medical and care facilities, and property leasing for healthcare and other tenants. Its Medical Supply segment focuses on the distribution of essential materials for medical examinations, treatments, and specialized care. The Life Care segment manages senior living residences, group homes, and other specialized facilities, alongside providing nutritional services. Through its Dispensing Pharmacy segment, the company operates retail pharmacies. Founded in 1992, Ship Healthcare Holdings maintains its corporate headquarters in Suita, Japan.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
JPY2,298.00 +11.00 (+0.48%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
249.9K
Beta
-0.06
Float Shares
74.75M
Free Float %
81.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.03% -9.12% -16.05% -24.72% -19.98% -21.74% -2.11% -18.62% -22.39% +43.76% +252.65%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
2,298.00
DCF (Unlevered) 7,480.39 +225.5%
DCF (Levered) 7,932.87 +245.2%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 33% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 0 -1
Hold 2 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.22
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Instruments & Supplies: +7.9%
    +5.9% Q1'26: +5.3% (vs Q1'25)
  • ✗
    EPS growth Medical - Instruments & Supplies: +16.3%
    -10.1% Q1'26: -11.0% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    +2.6% ★ Q1'26: +0.0% (vs Q1'25)
  • ✗
    EBIT margin Medical - Instruments & Supplies: +13.5%
    +3.4% Q1'26: +5.1% (vs Q1'25)
  • ✗
    ROIC Medical - Instruments & Supplies: +6.0%
    +14.3% ★ Q1'26: +23.5% (vs Q1'25)
  • ✓
    Share dilution Medical - Instruments & Supplies: +0.1%
    -1.5% ★ Q1'26: -2.2% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    0.96× ★ Q1'26: 0.64× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.23) × ERP
WACC = 84% × Ke + 16% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 7,480.39 Current price: 2,298.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
4 Rev. Ana.
4 EPS Ana. 		Mar 2027
4 Rev. Ana.
4 EPS Ana. 		Mar 2028
3 Rev. Ana.
3 EPS Ana. 		Mar 2029
2 Rev. Ana.
2 EPS Ana. 		Mar 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
273.33B
est: 277.53B (-1.5%)
306.85B
est: 304.67B (+0.7%)
408.49B
est: 416.17B (-1.8%)
425.57B
est: 432.58B (-1.6%)
444.05B
est: 447.39B (-0.7%)
484.40B
est: 480.65B (+0.8%)
497.16B
est: 496.43B (+0.1%)
514.35B
est: 506.72B (+1.5%)
572.29B
est: 572.29B (+0.0%)
630.99B
est: 639.74B (-1.4%)
678.23B
est: 675.45B (+0.4%)
711.53B
701.44B – 720.88B
+5.3% YoY
752.40B
741.44B – 765.67B
+5.7% YoY
798.95B
794.24B – 803.66B
+6.2% YoY
833.70B
826.33B – 841.08B
+4.3% YoY
882.80B
869.94B – 898.37B
+5.9% YoY
EBITDA
17.02B
est: 13.87B (+22.7%)
18.63B
est: 15.23B (+22.3%)
20.59B
est: 20.80B (-1.0%)
22.45B
est: 21.62B (+3.8%)
22.32B
est: 22.36B (-0.2%)
24.03B
est: 24.03B (+0.0%)
26.30B
est: 24.82B (+6.0%)
26.23B
est: 25.33B (+3.6%)
28.61B
est: 28.61B (0.0%)
31.88B
est: 32.22B (-1.1%)
32.16B
est: 34.02B (-5.5%)
35.84B
35.33B – 36.31B
+5.3% YoY
37.89B
37.34B – 38.56B
+5.7% YoY
40.24B
40.00B – 40.48B
+6.2% YoY
41.99B
41.62B – 42.36B
+4.3% YoY
44.46B
43.81B – 45.25B
+5.9% YoY
EBIT
13.17B
est: 10.73B (+22.8%)
14.13B
est: 11.78B (+20.0%)
15.92B
est: 16.09B (-1.0%)
18.27B
est: 16.72B (+9.2%)
17.81B
est: 17.30B (+3.0%)
19.18B
est: 18.58B (+3.2%)
21.17B
est: 19.19B (+10.3%)
20.74B
est: 19.59B (+5.9%)
21.16B
est: 22.12B (-4.4%)
24.45B
est: 24.97B (-2.1%)
24.79B
est: 26.37B (-6.0%)
27.77B
27.38B – 28.14B
+5.3% YoY
29.37B
28.94B – 29.89B
+5.7% YoY
31.19B
31.00B – 31.37B
+6.2% YoY
32.54B
32.26B – 32.83B
+4.3% YoY
34.46B
33.96B – 35.07B
+5.9% YoY
Net Income
7.47B
est: 8.83B (-15.3%)
8.85B
est: 7.94B (+11.4%)
9.41B
est: 8.87B (+6.1%)
10.35B
est: 10.12B (+2.3%)
11.24B
est: 10.57B (+6.3%)
11.80B
est: 12.11B (-2.6%)
12.28B
est: 13.30B (-7.7%)
12.17B
est: 11.12B (+9.4%)
12.06B
est: 11.50B (+4.9%)
13.80B
est: 13.86B (-0.4%)
15.13B
est: 15.75B (-4.0%)
16.02B
15.63B – 16.53B
+1.7% YoY
17.18B
16.61B – 18.83B
+7.2% YoY
18.11B
17.89B – 20.71B
+5.5% YoY
22.39B
21.24B – 23.53B
+23.6% YoY
24.48B
24.02B – 25.05B
+9.4% YoY
SGA
21.35B
est: 18.02B (+18.5%)
22.08B
est: 19.78B (+11.6%)
28.24B
est: 27.02B (+4.5%)
28.46B
est: 28.09B (+1.3%)
28.58B
est: 29.05B (-1.6%)
30.11B
est: 31.21B (-3.5%)
32.96B
est: 32.23B (+2.2%)
32.47B
est: 32.90B (-1.3%)
39.08B
est: 37.16B (+5.2%)
40.74B
est: 41.39B (-1.6%)
41.49B
est: 43.70B (-5.0%)
46.03B
45.38B – 46.63B
+5.3% YoY
48.67B
47.96B – 49.53B
+5.7% YoY
51.69B
51.38B – 51.99B
+6.2% YoY
53.93B
53.46B – 54.41B
+4.3% YoY
57.11B
56.28B – 58.12B
+5.9% YoY
EPS
84.22
est: 93.55 (-10.0%)
89.54
est: 84.17 (+6.4%)
93.15
est: 93.98 (-0.9%)
102.27
est: 107.23 (-4.6%)
113.87
est: 112.06 (+1.6%)
124.01
est: 128.39 (-3.4%)
129.99
est: 140.98 (-7.8%)
129.01
est: 117.90 (+9.4%)
127.85
est: 121.90 (+4.9%)
146.25
est: 146.86 (-0.4%)
160.34
est: 166.64 (-3.8%)
171.07
165.69 – 175.22
+2.7% YoY
187.25
176.06 – 199.53
+9.5% YoY
202.95
189.60 – 219.55
+8.4% YoY
237.30
225.16 – 249.44
+16.9% YoY
259.50
254.59 – 265.45
+9.4% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-12 A 4/5 5/5 4/5 4/5 2/5 3/5 4/5
2026-05-11 A 4/5 5/5 4/5 4/5 2/5 3/5 4/5
2026-05-08 A 4/5 5/5 4/5 4/5 2/5 3/5 4/5
2026-05-07 A 4/5 5/5 4/5 4/5 2/5 3/5 4/5
2026-05-01 A- 4/5 5/5 3/5 4/5 2/5 3/5 4/5
2026-04-30 A- 4/5 5/5 3/5 4/5 2/5 3/5 4/5
2026-04-28 A- 4/5 5/5 3/5 4/5 2/5 3/5 4/5
2026-04-27 A- 4/5 5/5 3/5 4/5 2/5 3/5 4/5
2026-04-24 A- 4/5 5/5 3/5 4/5 2/5 3/5 4/5
2026-04-23 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-22 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-21 A- 4/5 5/5 3/5 5/5 1/5 3/5 4/5
2026-04-20 A- 4/5 5/5 3/5 5/5 1/5 3/5 4/5
2026-04-17 A- 4/5 5/5 3/5 5/5 1/5 3/5 4/5
2026-04-16 A- 4/5 5/5 3/5 5/5 1/5 3/5 4/5
2026-04-15 A- 4/5 5/5 3/5 5/5 1/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
6.22B
OE per share TTM
63.62
Owner's Yield
2.99%
Maintenance CapEx ratio
46.20%
Maint CapEx / Avg PPE
8.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
3.12M
Shares Outstanding
92.02M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Atsushi Umino MD, Head of Sales Strategy, Head of FD Business & Director — —
Futoshi Ohashi President, GM of Corporate Planning Dept and Efficiency Planning Headquarters & Director — male
Hirotaka Ogawa Vice Chairman & GM of the TPP Business Unit — male
Kenzo Konishi Vice Chairman & GM of MSP Business Division — male
Yoshio Yasuda GM of Administration Headquarters & Director — —
Yuji Yokoyama Senior MD, Chief Secretary, GM of Human Resources Development Headquarters & Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Instruments & Supplies